Courtney Phillips - 01 Sep 2026 Form 4 Insider Report for Maze Therapeutics, Inc. (MAZE)

Reporting relationship: GC and Corp. Secretary
Issuer ticker: MAZE
Reported as of: 01 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Sep 2026, 16:31:00 UTC
Prior SEC filing: 03 Mar 2026
Next SEC filing: 04 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Courtney Phillips

Key filing fact

Courtney Phillips filed Form 4 for Maze Therapeutics, Inc. (MAZE) on 03 Sep 2026.

Key facts

This page summarizes Courtney Phillips's Form 4 filing for Maze Therapeutics, Inc. (MAZE).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Sep 2026, 16:31.

Change

Previous filing in this sequence was filed on 03 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001782758 Primary reporting owner

Courtney Phillips

Relationship: GC and Corp. Secretary
Address: C/O MAZE THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Signature: /s/ Courtney Phillips
Signature date: 03 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MAZE transaction

Common Stock

Options Exercise

Transaction value
Shares: +11,000
Change %
Price: $0.000000^*
Shares after: 11,000
Date: 01 Sep 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MAZE transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -11,000
Change %: -50%
Price: $0.000000^*
Shares after: 11,000
Date: 01 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,000
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

Footnote F2

The award vested or vests as to 1/2 of the total award on September 1, 2026 and September 1, 2027, subject to the reporting person's continued service to the Issuer on each vesting date.

Footnote F3

These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.